力生制药(002393.SZ)：子公司中央药业药品阿普米司特片通过上市许可申请

Core Viewpoint - The company, Lifesun Pharmaceutical (002393.SZ), announced that its subsidiary, Tianjin Central Pharmaceutical Co., Ltd., has received drug registration certificates from the National Medical Products Administration for Apremilast tablets in three dosages: 10mg, 20mg, and 30mg, indicating successful approval for market entry [1] Group 1 - The drug Apremilast is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy [1] - The registration certificates have the following batch numbers: 2025S03538 for 10mg, 2025S03539 for 20mg, and 2025S03540 for 30mg [1]